Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | TACR1 | P25103 | 4/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14343619 | 1.00 | RORC (0.46) | RORCGPR119RIPK1TACR1NR1H2 | |
| SCHEMBL830156 | 1.00 | RORC (0.46) | RORCGPR119RIPK1TACR1NR1H2 | |
| SCHEMBL30700513 | 1.00 | RORC (0.46) | RORCGPR119RIPK1TACR1NR1H2 | |
| SCHEMBL830155 | 1.00 | RORC (0.46) | RORCGPR119RIPK1TACR1NR1H2 | |
| SCHEMBL29063356 | 1.00 | RORC (0.46) | RORCGPR119RIPK1TACR1NR1H2 | |
| SCHEMBL4198304 | 1.00 | RORC (0.46) | RORCGPR119RIPK1TACR1NR1H2 | |
| SCHEMBL1595217 | 1.00 | RORC (0.46) | RORCGPR119RIPK1TACR1NR1H2 | |
| SCHEMBL15185071 | 1.00 | RORC (0.46) | RORCGPR119RIPK1TACR1NR1H2 | |
| SCHEMBL829709 | 0.92 | RIPK1 (0.51) | RORCGPR119RIPK1HCRTR2 | |
| SCHEMBL829779 | 0.92 | RIPK1 (0.51) | RORCGPR119RIPK1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9718840-B2 | Condensed 5-oxazolidinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9718840-B2 | Condensed 5-oxazolidinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9718840-B2 | Condensed 5-oxazolidinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-6083903-A | REDUCE RATE OF DEGRADATION OF PROTEINS IN ANIMAL | LEUKOSITE, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-6066730-A | Boronic ester and acid compounds, synthesis and uses | PROSCRIPT, INC. | 2000-05-23 | — | — | US | disclosed |
| EP-0675899-B1 | NOVEL INHIBITORS OF FACTOR Xa | CORVAS INT INC (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5883077-A | PEPTIDES ALDEHYDE ANALOGUES | CORVAS INTERNATIONAL, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5780454-A | Boronic ester and acid compounds | PROSCRIPT, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0788360-A4 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT INC (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5739112-A | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0788360-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| WO-1994013693-A1 | NOVEL INHIBITORS OF FACTOR Xa | CORVAS INTERNATIONAL, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | RORC 3408/4885GPR119 4843/4885RIPK1 1042/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | RORC 3343/4885GPR119 4800/4885RIPK1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.